Tradipitant for Functional Dyspepsia

Pharmacodynamics, Pharmacogenetics, Clinical Efficacy and Safety of Tradipitant for Functional Dyspepsia

Status

Enrolling by invitation

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05653310

Enrollment

Registered

2022-12-16

Start date

2023-02-09

Completion date

2027-03-01

Last updated

2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia

Keywords

tradipitant, NK-1 antagonist, neurokinin 1 receptor

Brief summary

To evaluate the effects of tradipitant relative to placebo on gastric motor functions, satiation, and postprandial symptoms in patients with functional dyspepsia.

Interventions

DRUGTradipitant

Tradipitant Capsule

DRUGPlacebo

Placebo Capsule

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Able to provide written consent * Body Mass Index (BMI) of 18-35 kg/m2 * Absence of other diseases which could interfere with interpretation of study results

Exclusion criteria

* Current H. pylori infection * Pregnancy or nursing * Recent history of Alcohol Use Disorder or Substance Use Disorder

Design outcomes

Primary

Measure	Time frame
Accommodation gastric volumes measured by single photon emission computed tomography (SPECT)	4 Weeks

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORXiao Jing (Iris) Wang, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026